Guggenheim Starts Coverage on Sagimet Biosciences with Buy Rating
Guggenheim analyst gives Sagimet Biosciences a Buy rating with $27 target, citing promising results for its FASN inhibitor in MASH and acne.
/ 3 items
#SGMT↓
Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.
FDA Breakthrough: New Non-Invasive Biomarker to Revolutionize MASH Drug Development
The FDA accepted non-invasive Liver Stiffness Measurement as a surrogate endpoint for MASH clinical trials, replacing biopsies. This key decision accelerates MASH drug development by enabling safer monitoring, speeding recruitment, and predicting patient outcomes.